Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma

Purpose: The multidrug resistance 1 (MDR1) gene expression and its epigenetic status may be an important factor in the chemotherapeutic resistance of glioblastoma (GB). The aim of this study was to analyze the effect of the MDR1 promoter methylation status on GB tumor tissue related to patient survi...

Full description

Saved in:
Bibliographic Details
Published in:Pamukkale Medical Journal 2022-01, Vol.15 (3), p.547-554
Main Authors: Güner,Yahya Efe, Bayatlı,Eyüp, Kurt Kızıldoğan,Aslıhan, Gökmen,Derya, Yüksek,Veysel, Taşpınar,Filiz, Tetik,Bora, Taşpınar,Mehmet, Uğur,Hasan Çağlar
Format: Article
Language:English
Subjects:
Brain cancer
Chemotherapy
Gene expression
Multidrug resistant organisms
Patients
Sağlık Hizmetleri
Tıp
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: The multidrug resistance 1 (MDR1) gene expression and its epigenetic status may be an important factor in the chemotherapeutic resistance of glioblastoma (GB). The aim of this study was to analyze the effect of the MDR1 promoter methylation status on GB tumor tissue related to patient survival, chemotherapy resistance, and recurrence of the disease. Materials and methods: Thirty-six patients underwent surgery for GB at the Neurosurgery Department of Ankara University School of Medicine. The patients’ clinical information and the MDR1 methylation status of the tumor tissues were compared to determine the effects on patient survival, chemotherapy resistance, and tumor recurrence. Results: Patients with MDR1 methylated GB had statistically significantly (p
ISSN:1309-9833
1308-0865
DOI:10.31362/patd.1013078